Immunoglobulin A nephropathy (IgAN) is an immune-complex-mediated glomerulonephritis characterized by the presence of IgA deposits in mesangial and paramesangial regions. However, the exact mechanism involved in IgA deposition is still unknown. TGF-β(1) that mediates the progression of IgAN is well established as a critical IgA class (isotype) switching factor, and Smad proteins are critical intracellular mediators in the expression of TGF-β(1)-targeted genes, which suggest that TGF-β signaling has been implicated in the primary pathogenesis of IgAN. Arkadia, an E3 ubiquitin ligase, can amplify TGF-β signaling through regulating Smads degradation. When these findings are considered together, it is of interest to explore how Arkadia and Smad signaling affect TGF-β(1)-induced IgA expression in IgAN. Therefore, we propose that Arkadia could positively contribute to TGF-β(1)-induced IgA secretion through up-regulation of Smad signaling in the pathogenesis of IgAN.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11255-009-9682-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The primiparous IgA and IL-5 colostrum concentration based on maternal factor: corroborate the inflammation pathways to IgA colostrum synthesis.
AJOG Glob Rep
February 2025
Center for Biomedical Research, Research Organization for Health, National Research and Innovation Agency (BRIN) (Nurwidyaningtyas), Bogor, West Java, Indonesia.
Background: Immunoglobulin A (IgA) plays a crucial role in the maturation the neonatal mucosal barrier. The accumulation of IgA antibody-secreting cells (ASCs) in the lactating mammary gland facilitates the secretion of IgA antibodies into milk, which are then passively to the suckling newborn, providing transient immune protection against gastrointestinal pathogens. Physiologically, full-term infants are unable to produce IgA, required for mucosal barrier maturation for at least 10 days after birth.
View Article and Find Full Text PDFLinear IgA bullous dermatosis-a fifty year experience of Warsaw Center of bullous diseases.
Front Immunol
January 2025
Department of Immunodermatology, National Medical Institute of the Ministry of the Interior and Administration, Warsaw, Masovian, Poland.
Linear IgA bullous dermatosis (LABD) is a rare subepidermal blistering disorder characterized by the presence of linear IgA deposits at the basement membrane zone (BMZ) by direct immunofluorescence (DIF). This entity was first described by Chorzelski and Jablonska from Warsaw Center of Bullous Diseases, Poland. The disease affects children and adults, whereby they differ in terms of clinical picture and course.
View Article and Find Full Text PDFObservation of the clinical characteristics of chronic diarrhoea in children and evaluation of the prognostic value of nutritional and immune indicators.
J Med Biochem
November 2024
Children's Hospital of Capital Institute of Pediatrics, Department of Gastroenterology, Beijing City, China.
Background: This research aimed to assess the clinical characteristics of chronic diarrhoea in children and explore the prognostic value of nutritional status and immune indicators.
Methods: A total of 190 patients with chronic diarrhoea from January 2017 to June 2020 were enrolled to analyze their epidemiology. The patients were divided into a better prognosis group (cured and improved) and a poor prognosis group (uncured).
Targeted modulation of intestinal barrier and mucosal immune-related microbiota attenuates IgA nephropathy progression.
Gut Microbes
December 2025
State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China.
IgA nephropathy (IgAN) is related to the balance of gut microbiota. However, it is unclear whether changes in the gut microbiota can cause IgAN or attenuate its progression. This study employed IgAN and human microbiota-associated (HMA)-IgAN models to investigate the impact of IgAN on gut microbiota alteration and the mechanisms by which gut microbiota might trigger IgAN.
View Article and Find Full Text PDFEfficacy and Safety of Proactive Therapy with 2% Crisaborole Ointment in Children with Mild-to-Moderate Atopic Dermatitis: A Randomized Controlled Study.
Paediatr Drugs
January 2025
Department of Dermatology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, China.
Background: The effectiveness of crisaborole for proactive treatment of atopic dermatitis (AD) is not well established.
Objectives: This study aims to investigate the efficacy and safety of a proactive treatment strategy with 2% crisaborole ointment for managing mild-to-moderate AD in children.
Patients And Methods: In this 16-week randomized-controlled trial, children aged 2-17 years with mild-to-moderate AD were enrolled.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!